Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?
Main finding · DMARD costs, autoantibody-negative RAResult — go to the resultβ 4.16 95% CI 1.57–11.1Authors' conclusion
When RA is detected within 12 weeks after symptom onset, treatment-related costs were lower in both autoantibody-negative and autoantibody-positive RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) consecutively included in the Leiden Early Arthritis Clinic, 2011–2017
- Participants
- 431 patients
- Exposure
- Early vs late treatment start in RA
- Outcome
- Treatment-related (DMARD) costs over 5 years
- Follow-up
- 5 years
Methodological detailsconsecutive inclusion, Leiden Early Arthritis Clinic
- Consecutive inclusion
- Leiden Early Arthritis Clinic
Main finding
DMARD costs, autoantibody-negative RA
β
4.16
95% CI 1.57–11.1
By group
Late
€4856
Early
€1159
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Early | Late | β (CI) |
|---|---|---|---|
| DMARD costs, autoantibody-positive RA · 5 yearsCosts 19% higher; smaller with 2012 prices | €7934 | €9418 | 1.19 (0.57–2.47) |
| Costs, autoantibody-positive RA using biologicals · 5 years46% higher costs; higher also with 2012 prices | 1.46 (0.91–2.33) |
Original publication
Early identification of rheumatoid arthritis: does it induce treatment-related cost savings? Ann Rheum Dis. Published 14 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →